详细资料
人物经历
1999年毕业于四川大学化学学院，获物理化学专业博士学位。
1995年，新加坡南洋理工大学访问学者。
1999年-2001年，香港科技大学化学系博士后。
2003年1月-2005年10月，加拿大Calgary大学研究助理，同时兼任Bayer公司高级研究员。
2005年10月通过985平台进入四川大学华西医院生物治疗国家重点实验室工作，主要从事药物分子设计方法、先导化合物优化、靶向药物设计、合成与开发等研究工作。
任职：
四川省药学会药物化学专委会副主任委员。
四川省肿瘤学会靶向治疗专委会委员。
《Pharmacology&Pharmacy》编委。
《J.Amer.Chem.Soc.》特邀审稿人。
《J.Med.Chem.》特邀审稿人。
《Proteins》特邀审稿人。
《J.Chem.Inf.Mod.》特邀审稿人。
《J.Theor.Comput.Chem.》特邀审稿人。
《Eur.J.Med.Chem.》特邀审稿人。
《Bioorg.Med.Chem.Lett.》特邀审稿人。
研究方向
(1)新型抗肿瘤靶向药物的研发。
(2)新型治疗自身免疫性疾病药物的研发。
(3)先导化合物优化与合成研究。
(4)药物分子设计新方法研究。
(5)系统生物学。
主要贡献
主持了包括863、国家创新药物重大专项、国家自然科学基金、教育部新世纪优秀人才资助计划、四川省杰出青年基金等多项国家和省部级项目。至今已在包括Leukemia,J.Amer.Chem.Soc.,ClinicaCancerRes.,DrugDisc.Today,J.Med.Chem.,PlosONE,Proteins,J.Comput.Chem.,Organometallics,J.Phys.Chem.A等国内外重要期刊上发表SCI研究论文100余篇。曾获四川省科技进步奖一项。研究领域：计算机辅助药物分子设计；计算生物学。
代表性论著：
Zhi-XingCao,Jing-JingLiu,Ren-LinZheng,JiaoYang,LeiZhong,YongXu,Li-JiaoWang,Chun-HunZhang,Bing-LinWang,ShuangMa,Huan-ZhangXie,Yu-QuanWei,andSheng-YongYang*.SKLB1028,anoveloralmultikinaseinhibitorofEGFR,FLT3andAbl,displaysexceptionalactivityinmodelsofFLT3-drivenAMLandconsiderablepotencyinthatofCMLharboringAblmutants.Leukemia,2012.Inpress。
LiWW,WangXY,ZhengRL,YanHX,CaoZX,ZhongL,WangZR,JiP,YangLL,WangLJ,XuY,LiuJJ,YangJ,ZhangCH,MaS,FengS,SunQZ,WeiYQ,YangSY*.DiscoveryoftheNovelPotentandSelectiveFLT3Inhibitor1-{5-[7-(3-Morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylureaandItsAnti-AcuteMyeloidLeukemia(AML)ActivitiesinVitroandinVivo.JMedChem.2012,55,3852-3866。
YouliPan,YongXu,ShanFeng,ShidongLuo,RenlinZheng,JiaoYang,LijiaoWang,LeiZhong,Han-YuYang,Bing-LinWang,YangYu,JingjingLiu,ZhixingCao,XiaoyanWang,PanJi,ZerongWang,XinChen,ShuangZhang,Yu-QuanWei,andSheng-YongYang*.SKLB1206,aNovelOrallyAvailableMultikinaseInhibitorTargetingEGFRActivatingandT790MMutants,ErbB2,ErbB4,andVEGFR2,DisplaysPotentAntitumorActivitybothInvitroandInvivo.MolCancerTher.2012,11(4),952-962。
WanHL,WangZR,LiLL,ChengC,JiP,LiuJJ,ZhangH,ZouJ,YangSY*.DiscoveryofnovelBruton'styrosinekinase(Btk)inhibitorsusingahybridprotocolofvirtualscreeningapproachesbasedonSVMmodel,pharmacophore,andmoleculardocking.ChemBiolDrugDes.2012.doi:10.1111/j.1747-02852012.01415.x。
Di-WuL,LiLL,WangWJ,XieHZ,YangJ,ZhangCH,HuangQ,ZhongL,FengS,YangSY*。IdentificationofCK2inhibitorswithnewscaffoldsbyahybridvirtualscreeningapproachbasedonBayesianmodel;pharmacophorehypothesisandmoleculardocking.JMolGraphModel.2012,36,42-47。
Xiao-YuQing,Chun-HuiZhang,Lin-LiLi,PanJi,ShuangMa,Hua-LinWan,Ze-RongWang,JunZou,andSheng-YongYang*.RetrievingNovelC5aRAntagonistsusingaHybridLigand-basedVirtualScreeningProtocolbasedonSVMClassificationandPharmacophoreModels.JBiomolStructDyn.2012,inpress。
ZhongL,MaCY,ZhangH,YangLJ,WanHL,XieQQ,LiLL,YangSY*Apredictionmodelofsubstratesandnon-substratesofbreastcancerresistanceprotein(BCRP)developedbyGA-CG-SVMmethod.ComputBiolMed.2011Nov;41(11):1006-13。
HuangQ,LiLL,YangSY*.RASA:arapidretrosynthesis-basedscoringmethodfortheassessmentofsyntheticaccessibilityofdrug-likemolecules.JChemInfModel.2011Oct24;51(10):2768-77。
ZhouJP,ChenX,FengS,LuoSD,PanYL,ZhongL,JiP,WangZR,MaS,LiLL,WeiYQ,YangSY*SystemsBiologyModelingRevealsaPossibleMechanismoftheTumorCellDeathuponOncogeneInactivationinEGFRAddictedCancers.PLoSOne.2011;6(12):e28930。
RenJX,LiLL,ZhengRL,XieHZ,CaoZX,FengS,PanYL,ChenX,WeiYQ,YangSY*DiscoveryofnovelPim-1kinaseinhibitorsbyahierarchicalmultistagevirtualscreeningapproachbasedonSVMmodel,pharmacophore,andmoleculardocking.JChemInfModel.2011Jun27;51(6):1364-75。
XieQQ,ZhongL,PanYL,WangXY,ZhouJP,Di-WuL,HuangQ,WangYL,YangLL,XieHZ,YangSY*CombinedSVM-basedanddocking-basedvirtualscreeningforretrievingnovelinhibitorsofc-Met.EurJMedChem.2011,46,3675-3680。
ZhangH,LiW,XieY,WangWJ,LiLL,YangSY*.Rapidandaccurateassessmentofseizureliabilityofdrugsbyusinganoptimalsupportvectormachinemethod.ToxicolInVitro.2011,25,1848–1854。
XieHZ,LiuLY,RenJX,ZhouJP,ZhengRL,LiLL,YangSY*.PharmacophoremodelingandhybridvirtualscreeningforthediscoveryofnovelIκBkinase2(IKK2)inhibitors.JBiomolStructDyn.2011,29(1):165-79。
DongX,EbalunodeJO,YangSY,ZhengW.Receptor-basedpharmacophoreandpharmacophorekeydescriptorsforvirtualscreeningandQSARmodeling.CurrComputAidedDrugDes.2011Sep1;7(3):181-9。
ZengXF,LiWW,FanHJ,WangXY,JiP,WangZR,MaS,LiLL,MaXF,YangSY*Discoveryofnovelfattyacidsynthase(FAS)inhibitorsbasedonthestructureofketoaceylsynthase(KS)domain.BioorgMedChemLett.2011Aug15;21(16):4742-4。
Guo-BoLi,Ling-LingYang,ShanFeng,Jian-PingZhou,QiHuang,Huan-ZhangXie,Lin-LiLi,Sheng-YongYang*.DiscoveryofnovelmGluR1antagonists:AmultistepvirtualscreeningapproachbasedonanSVMmodelandapharmacophorehypothesissignificantlyincreasesthehitrateandenrichmentfactor.BioorgMedChemLett.2011Jan25.[Epubaheadofprint]。
JunZou,Shi-DongLuo,Yu-QuanWeiandSheng-YongYang*,IntegratedcomputationalmodelofcellcycleandcheckpointrevealsdifferentessentialrolesofAurora-AandPlk1inmitoticentry.Mol.BioSyst.,2011,7,169–179。
QiHuang,Lin-LiLi,Sheng-YongYang*.PhDD:Anewpharmacophore-baseddenovodesignmethodofdrug-likemoleculescombinedwithassessmentofsyntheticaccessibility.JournalofMolecularGraphicsandModelling.2010,28,775-787。
Wei-WeiLi,Jin-JuanChen,Ren-LinZheng,Wen-QinZhang,Zhi-XingCao,Ling-LingYang,Xiao-YuQing,Liang-XueZhou,LiYang,Luo-DingYu,Li-JuanChen,Yu-QuanWei,andSheng-YongYang*.Takingquinazolineasageneralsupport-nogtodesignpotentandselectivekinaseinhibitors:applicationtoFMS-liketyrosinekinase3.ChemMedChem.2010,5,513-516。
Sheng-YongYang*.Pharmacophoremodelingandapplicationsindrugdiscovery:challengesandrecentadvances.DrugDiscoveryToday.2010,15,444-450。
Li-JunYang,JunZou,Huan-ZhangXie,Lin-LiLi,Yu-QuanWei,Sheng-YongYang*.Steeredmoleculardynamicssimulationsrevealthelikelierdissociationpathwayofimatinibfromitstargetingkinasesc-KitandAbl.PLOSOne.2009,4,e8470。
Ji-XiaRen,Lin-LiLi,JunZou,LiYang,Jin-LiangYang,Sheng-YongYang*.Pharmacophoremodelingandvirtualscreeningforthediscoveryofnewtransforminggrowthfactor-btypeIreceptor(ALK5)inhibitors.EuropeanJournalofMedicinalChemistry.2009,44,4259-4265。
Huan-ZhangXie,Lin-LiLi,Ji-XiaRen,JunZou,Yu-QuanWei,andSheng-YongYang*.Pharmacophoremodelingstudybasedonknownspleentyrosinekinaseinhibitorstogetherwithvirtualscreeningforidentifyingnovelinhibitors.Bioorganic&MedicinalChemistryLetters.2009,19,1944-1949。
Jin-JuanChen,Ting-LinLiu,Li-JunYang,Lin-LiLi,Yu-QuanWeiandSheng-YongYang*.Pharmacophoremodelingandvirtualscreeningstudiesofcheckpointkinase1inhibitors.Chem.Pharm.Bull.2009,57,704-709。
Sheng-YongYang*,QiHuang,Lin-LiLi,Chang-YingMa,HuiZhang,RuBai,Qi-ZhiTeng,Ming-LiXiang,Yu-QuanWei.Anintegratedschemeforfeatureselectionandparametersettinginthesupportvectormachinemodelinganditsapplicationtothepredictionofpharmacokineticpropertiesofdrugs.ArtificialIntelligenceinMedicine.2009,46,155-163。
HuiZhang,Ming-LiXiang,Chang-YingMa,QiHuang,WeiLi,YangXie,Yu-QuanWei,Sheng-YongYang*.Three-classclassificationmodelsoflogSandlogPderivedbyusingGA-CG-SVMapproach.MolecularDiversity.2009,13,261-268。
LijunYang,RuoJia,Sheng-YongYang*.InfluenceofthesolventwatermoleculesattheactivesiteofCDK2onthebindingfreeenergyofCDK2-ligandcomplexes:anMM/PBSAstudy.ActaChimicaSinica.2009,67,255-260。
HuiZhang,Qing-YiChen,Ming-LiXiang,Chang-YingMa,QiHuangandSheng-YongYang*.InsilicopredictionofmitochondrialtoxicitybyusingGA-CG-SVMapproach.Toxicityinvitro,2009,23,134–140。
Hui-YuanWang,Lin-LiLi,Zhi-XingCao,Shi-DongLuo,Yu-QuanWeiandSheng-YongYang*.AspecificpharmacophoremodelofAuroraBkinaseinhibitorsandvirtualscreeningstudiesbasedonit.ChemicalBiology&DrugDesign.2009,73(1),115-126。
Ting-linLiu,Huan-zhangXie,Yu-quanWei,Sheng-YongYang*.Exploringthefeasibilityofapplicationofreversedockingmethodtotheselectivitystudiesofproteinkinaseinhibitors.ActaPharmaceuticaSinica.2009,44(7),758-763。
Qing-QingXie,Huan-ZhangXie,Jie-XiaRen,Lin-LiLi,andSheng-YongYang*.PharmacophoremodelingstudiesoftypeIandtypeIIkinaseinhibitorsofTie2.JournalofMolecularGraphicsandModelling.2009,27,751–758。
HuiZhang,Ming-LiXiang,Ying-LanZhao,Yu-QuanWeiandSheng-YongYang*.Supportvectormachineandpharmacophore-basedpredictionmodelsofmultidrug-resistanceprotein2(MRP2)inhibitors.EuropeanJournalofPharmaceuticalSciences.2009,36,451–457。